Robert P Dickson1,2, John R Erb-Downward1, Nicole R Falkowski1, Ellen M Hunter1, Shanna L Ashley1, Gary B Huffnagle1,3,4,5. 1. 1 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and. 2. 2 Michigan Center for Integrative Research in Critical Care, Ann Arbor, Michigan; and. 3. 3 Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan. 4. 4 Department of Molecular, Cellular, and Developmental Biology and. 5. 5 Mary H. Weiser Food Allergy Center, University of Michigan, Ann Arbor, Michigan.
Abstract
RATIONALE: The "gut-lung axis" is commonly invoked to explain the microbiome's influence on lung inflammation. Yet the lungs harbor their own microbiome, which is altered in respiratory disease. The relative influence of gut and lung bacteria on lung inflammation is unknown. OBJECTIVES: To determine whether baseline lung immune tone reflects local (lung-lung) or remote (gut-lung) microbe-host interactions. METHODS: We compared lung, tongue, and cecal bacteria in 40 healthy, genetically identical, 10-week-old mice, using 16S ribosomal RNA gene quantification and sequencing. We measured inflammatory cytokines, using a multiplex assay of homogenized lung tissue. We compared lung bacteria in healthy mice treated with varied durations of systemic antibiotics. MEASUREMENTS AND MAIN RESULTS: Lung bacterial communities are highly variable among mice, cluster strongly by cage, shipment, and vendor, and are altered by antibiotics in a microbiologically predictable manner. Baseline lung concentrations of two key inflammatory cytokines (IL-1α and IL-4) are correlated with the diversity and community composition of lung bacterial communities. Lung concentrations of these inflammatory cytokines correlate more strongly with variation in lung bacterial communities than with that of the gut or mouth. CONCLUSIONS: In the lungs of healthy mice, baseline innate immune tone more strongly reflects local (lung-lung) microbe-host interactions than remote (gut-lung) microbe-host interactions. Our results independently confirm the existence and immunologic significance of the murine lung microbiome, even in health. Variation in lung microbiota is likely an important, underappreciated source of experimental and clinical variability. The lung microbiome is an unexplored therapeutic target for the prevention and treatment of inflammatory lung disease.
RATIONALE: The "gut-lung axis" is commonly invoked to explain the microbiome's influence on lung inflammation. Yet the lungs harbor their own microbiome, which is altered in respiratory disease. The relative influence of gut and lung bacteria on lung inflammation is unknown. OBJECTIVES: To determine whether baseline lung immune tone reflects local (lung-lung) or remote (gut-lung) microbe-host interactions. METHODS: We compared lung, tongue, and cecal bacteria in 40 healthy, genetically identical, 10-week-old mice, using 16S ribosomal RNA gene quantification and sequencing. We measured inflammatory cytokines, using a multiplex assay of homogenized lung tissue. We compared lung bacteria in healthy mice treated with varied durations of systemic antibiotics. MEASUREMENTS AND MAIN RESULTS: Lung bacterial communities are highly variable among mice, cluster strongly by cage, shipment, and vendor, and are altered by antibiotics in a microbiologically predictable manner. Baseline lung concentrations of two key inflammatory cytokines (IL-1α and IL-4) are correlated with the diversity and community composition of lung bacterial communities. Lung concentrations of these inflammatory cytokines correlate more strongly with variation in lung bacterial communities than with that of the gut or mouth. CONCLUSIONS: In the lungs of healthy mice, baseline innate immune tone more strongly reflects local (lung-lung) microbe-host interactions than remote (gut-lung) microbe-host interactions. Our results independently confirm the existence and immunologic significance of the murine lung microbiome, even in health. Variation in lung microbiota is likely an important, underappreciated source of experimental and clinical variability. The lung microbiome is an unexplored therapeutic target for the prevention and treatment of inflammatory lung disease.
Authors: Mairi C Noverr; Nicole R Falkowski; Rod A McDonald; Andrew N McKenzie; Gary B Huffnagle Journal: Infect Immun Date: 2005-01 Impact factor: 3.441
Authors: Markus J Ege; Melanie Mayer; Anne-Cécile Normand; Jon Genuneit; William O C M Cookson; Charlotte Braun-Fahrländer; Dick Heederik; Renaud Piarroux; Erika von Mutius Journal: N Engl J Med Date: 2011-02-24 Impact factor: 91.245
Authors: Aurélien Trompette; Eva S Gollwitzer; Koshika Yadava; Anke K Sichelstiel; Norbert Sprenger; Catherine Ngom-Bru; Carine Blanchard; Tobias Junt; Laurent P Nicod; Nicola L Harris; Benjamin J Marsland Journal: Nat Med Date: 2014-01-05 Impact factor: 53.440
Authors: Kurtis F Budden; Shaan L Gellatly; David L A Wood; Matthew A Cooper; Mark Morrison; Philip Hugenholtz; Philip M Hansbro Journal: Nat Rev Microbiol Date: 2016-10-03 Impact factor: 60.633
Authors: Danielle G Souza; Angélica T Vieira; Adriana C Soares; Vanessa Pinho; Jacques R Nicoli; Leda Q Vieira; Mauro M Teixeira Journal: J Immunol Date: 2004-09-15 Impact factor: 5.422
Authors: Mariel Slater; Damian W Rivett; Lisa Williams; Matthew Martin; Tim Harrison; Ian Sayers; Kenneth D Bruce; Dominick Shaw Journal: Thorax Date: 2013-11-28 Impact factor: 9.139
Authors: Min Yue; Jae Hyun Kim; Charles R Evans; Maureen Kachman; John R Erb-Downward; Jennifer D'Souza; Betsy Foxman; Sara D Adar; Jeffrey L Curtis; Kathleen A Stringer Journal: Am J Respir Crit Care Med Date: 2020-08-15 Impact factor: 21.405
Authors: Sharon M Carney; Jose C Clemente; Michael J Cox; Robert P Dickson; Yvonne J Huang; Georgios D Kitsios; Kirsten M Kloepfer; Janice M Leung; Tricia D LeVan; Philip L Molyneaux; Bethany B Moore; David N O'Dwyer; Leopoldo N Segal; Stavros Garantziotis Journal: Am J Respir Cell Mol Biol Date: 2020-03 Impact factor: 6.914
Authors: Antoine Guillon; Emad I Arafa; Kimberly A Barker; Anna C Belkina; Ian Martin; Anukul T Shenoy; Alicia K Wooten; Carolina Lyon De Ana; Anqi Dai; Adam Labadorf; Jaileene Hernandez Escalante; Hans Dooms; Hélène Blasco; Katrina E Traber; Matthew R Jones; Lee J Quinton; Joseph P Mizgerd Journal: JCI Insight Date: 2020-02-27
Authors: David N O'Dwyer; Shanna L Ashley; Stephen J Gurczynski; Meng Xia; Carol Wilke; Nicole R Falkowski; Katy C Norman; Kelly B Arnold; Gary B Huffnagle; Margaret L Salisbury; MeiLan K Han; Kevin R Flaherty; Eric S White; Fernando J Martinez; John R Erb-Downward; Susan Murray; Bethany B Moore; Robert P Dickson Journal: Am J Respir Crit Care Med Date: 2019-05-01 Impact factor: 21.405
Authors: Shanna L Ashley; Michael W Sjoding; Antonia P Popova; Tracy X Cui; Matthew J Hoostal; Thomas M Schmidt; William R Branton; Michael G Dieterle; Nicole R Falkowski; Jennifer M Baker; Kevin J Hinkle; Kristine E Konopka; John R Erb-Downward; Gary B Huffnagle; Robert P Dickson Journal: Sci Transl Med Date: 2020-08-12 Impact factor: 17.956
Authors: Robert P Dickson; Marcus J Schultz; Tom van der Poll; Laura R Schouten; Nicole R Falkowski; Jenna E Luth; Michael W Sjoding; Christopher A Brown; Rishi Chanderraj; Gary B Huffnagle; Lieuwe D J Bos Journal: Am J Respir Crit Care Med Date: 2020-03-01 Impact factor: 21.405